Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 15/20 | 0.75 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.40 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30057094 | 1.00 | IDO1 (0.75) | IDO1P2RX7MAPTCSNK1DCSNK1E | |
| SCHEMBL21496540 | 1.00 | IDO1 (0.75) | IDO1P2RX7MAPTCSNK1DCSNK1E | |
| SCHEMBL24118627 | 0.87 | IDO1 (0.80) | IDO1MAPT | |
| SCHEMBL30055212 | 0.87 | IDO1 (0.80) | IDO1MAPT | |
| SCHEMBL21496352 | 0.86 | IDO1 (1.00) | IDO1MAPT | |
| SCHEMBL21496354 | 0.86 | IDO1 (1.00) | IDO1MAPT | |
| SCHEMBL24118186 | 0.86 | IDO1 (1.00) | IDO1MAPT | |
| SCHEMBL23271162 | 0.84 | IDO1 (0.56) | IDO1 | |
| SCHEMBL29639833 | 0.84 | IDO1 (0.56) | IDO1 | |
| SCHEMBL21496325 | 0.82 | IDO1 (0.72) | IDO1MAPTIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3781142-A1 | NOVEL [1.1.1] BICYCLO COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | Merck Sharp&Dohme Corp. (US) | 2021-02-24 | — | — | EP | claimed |
| WO-2019204180-A1 | NOVEL [1.1.1] BICYCLO COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-10-24 | — | — | WO | claimed |